血塞通联合丁苯酞注射液治疗急性缺血性脑卒中病人的疗效及对血清学指标的影响

Effect of Xuesaitong combined with butylphthalide injection on PARK7、GFAP、CXCL12 and sVCAM-1 in patients with acute cerebral infarction

目的探讨血塞通联合丁苯酞注射液治疗急性缺血性脑卒中病人的疗效及对血清重组人帕金森病蛋白(PARK7)、神经胶质纤维酸性蛋白(GFAP)、趋化因子(CXCL)12和可溶性血管细胞黏附分子-1(sVCAM-1)水平的影响.方法选取安徽省亳州市人民医院2015年2月至2018年4月收治的89例急性缺血性脑卒中病人为研究对象,随机分为观察组(n=45)和对照组(n=44).对照组予以丁苯酞注射液治疗,观察组在此基础上加用血塞通治疗,2组疗程均为1周.比较2组治疗前后PARK7、GFAP、CXCL12和sVCAM-1水平的变化.结果治疗后,观察组血清PARK7、GFAP、CXCL12和sVCAM-1水平均低于对照组,差异均具有统计学意义(P<0.05).治疗后,观察组美国国立卫生研究院卒中量表(NIHSS)评分低于对照组,Barthel指数(BI)评分高于对照组,差异均具有统计学意义(P<0.05).观察组不良反应发生率为4.44%,对照组为6.81%,2组比较差异无统计学意义(P>0.05).结论血塞通联合丁苯酞注射液可有效改善急性缺血性脑卒中病人血清PARK7、GFAP、CXCL12和sVCAM-1水平,有助于改善病人的神经功能,具有较高的安全性,值得在临床中推广.

Objective To explore the effect of Xuesaitong combined with butylphthalide injection on PARK7、GFAP、CXCL12 and sVCAM-1 in the patients with acute cerebral infarction.Methods A total of 89 elderly patients with acute cerebral infarction from February 2015 to April 2018 in our hospital were recruited,and they were divided into observation group(n=45) and control group(n=44) randomly.The control group was given butylphthalide treatment,and the observation group was given Xuesaitong combined with butylphthalide injection treatment.The course of the treatment was one week in both groups.The clinical efficacy and the levels of PARK7、GFAP、CXCL12 and sVCAM-1 before and after treatment were compared between the two groups.Results After treatment,the levels of PARK7、 GFAP、 CXCL12 and sVCAM-1 in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the NIHSS score of the observation group was lower than that of the control group,while the BI score was higher,and the differences were statistically significant(P<0.05).The incidence rate of adverse reactions was 4.44% in the observation group and 6.81% in the control group,there was no difference between the two groups(P<0.05).Conclusions Xuesaitong combined with butylphthalide injection can effectively improve the serum levels of PARK7,GFAP,CXCL12 and sVCAM-1 in the patients with acute ischemic stroke.It is helpful to improve the neurological function of patients and has high safety.